Clinical Trials
16
9 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
Active, not recruiting
4
25.0%
Completed
4
25.0%
Enrolling By Invitation
1
6.3%
Not yet recruiting
4
25.0%
Terminated
2
12.5%
Withdrawn
1
6.3%
No approval data available
- New research from Target RWE presented at EASL 2025 demonstrates that individuals with Type 2 diabetes have significantly higher risk of progressing from MASH to cirrhosis, independent of age, sex, or fibrosis risk group. - The findings, co-authored by Dr. Michael Roden from Target RWE's MASH steering committee, emphasize the urgent need for early MASH detection in diabetic patients as MASLD prevalence continues to rise globally. - Target RWE has reached a milestone of over 600,000 patients enrolled in its TARGET-Liver Disease observational study, conducted in partnership with the American Association for the Study of Liver Diseases.
• Target RWE presented significant findings on MASH and HCC at EASL Congress 2025, revealing that Type 2 diabetes substantially increases the risk of progression to MASH-related cirrhosis. • The company's Chief Medical Officer participated in the PBC Consensus Conference, focusing on developing surrogate endpoints and integrating real-world evidence into clinical trials for Primary Biliary Cholangitis. • With over 600,000 patients enrolled in its TARGET-Liver Disease observational study, Target RWE continues to advance understanding of chronic liver diseases through its partnership with the American Association for the Study of Liver Diseases.
